Smoldering multiple myeloma (SMM) is explored through a patient case study, emphasizing the significance of monitoring and diagnosis. The evolution of diagnostic criteria and molecular mechanisms from precursor conditions to myeloma are discussed. The prevalence, risk factors, and stratification models for patient management are examined. Recent clinical trials highlight various treatment approaches, concluding with the need for individualized treatment plans for asymptomatic SMM based on risk assessment.

AI has been used for both descriptions and subtitles, even though it has been checked, there may be errors.